Hims & Hers Health, Inc. $HIMS is Steadview Capital Management LLC’s 6th Largest Position

Steadview Capital Management LLC lowered its position in Hims & Hers Health, Inc. (NYSE:HIMS) by 11.1% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 623,660 shares of the company’s stock after selling 78,185 shares during the period. Hims & Hers Health makes up 3.8% of Steadview Capital Management LLC’s holdings, making the stock its 6th biggest position. Steadview Capital Management LLC’s holdings in Hims & Hers Health were worth $20,250,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also made changes to their positions in HIMS. Farallon Capital Management LLC increased its position in Hims & Hers Health by 30.8% during the 3rd quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock worth $609,561,000 after purchasing an additional 2,533,271 shares in the last quarter. Invesco Ltd. increased its position in Hims & Hers Health by 62.7% during the 3rd quarter. Invesco Ltd. now owns 4,152,409 shares of the company’s stock worth $235,525,000 after purchasing an additional 1,600,004 shares in the last quarter. Clear Street Group Inc. purchased a new stake in Hims & Hers Health during the 3rd quarter worth about $87,372,000. Vanguard Group Inc. grew its holdings in Hims & Hers Health by 7.2% in the 4th quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company’s stock valued at $679,456,000 after buying an additional 1,407,651 shares during the period. Finally, BIT Capital GmbH grew its holdings in Hims & Hers Health by 73.8% in the 3rd quarter. BIT Capital GmbH now owns 2,210,384 shares of the company’s stock valued at $125,373,000 after buying an additional 938,728 shares during the period. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Price Performance

HIMS stock opened at $23.71 on Friday. The company has a current ratio of 1.69, a quick ratio of 1.56 and a debt-to-equity ratio of 2.18. Hims & Hers Health, Inc. has a 12-month low of $13.74 and a 12-month high of $70.43. The company has a market cap of $5.40 billion, a PE ratio of -263.46, a price-to-earnings-growth ratio of 46.59 and a beta of 2.43. The stock has a 50-day moving average price of $24.04 and a two-hundred day moving average price of $28.10.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, May 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.The firm had revenue of $608.10 million for the quarter, compared to analysts’ expectations of $616.84 million. During the same quarter in the previous year, the firm posted $0.20 EPS. The firm’s revenue for the quarter was up 3.8% compared to the same quarter last year. As a group, research analysts predict that Hims & Hers Health, Inc. will post 0.04 EPS for the current year.

Insider Transactions at Hims & Hers Health

In other news, CFO Oluyemi Okupe sold 7,950 shares of the business’s stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $23.64, for a total transaction of $187,938.00. Following the completion of the sale, the chief financial officer owned 262,954 shares in the company, valued at approximately $6,216,232.56. The trade was a 2.93% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Soleil Boughton sold 9,463 shares of the business’s stock in a transaction dated Monday, April 20th. The stock was sold at an average price of $30.00, for a total value of $283,890.00. Following the sale, the insider owned 299,368 shares of the company’s stock, valued at $8,981,040. The trade was a 3.06% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 212,807 shares of company stock worth $5,473,644 over the last 90 days. Company insiders own 11.76% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have commented on the company. Morgan Stanley lowered their price target on Hims & Hers Health from $40.00 to $21.00 and set an “equal weight” rating for the company in a report on Tuesday, February 24th. Canaccord Genuity Group set a $32.00 price target on Hims & Hers Health in a report on Tuesday, May 12th. JPMorgan Chase & Co. lowered their price target on Hims & Hers Health from $35.00 to $33.00 and set an “overweight” rating for the company in a report on Tuesday, May 12th. Bank of America lowered their price target on Hims & Hers Health from $30.00 to $28.00 and set a “neutral” rating for the company in a report on Tuesday. Finally, Citigroup lifted their price target on Hims & Hers Health from $24.00 to $28.00 and gave the company a “neutral” rating in a report on Tuesday, May 12th. Four research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Hims & Hers Health presently has a consensus rating of “Hold” and a consensus price target of $28.90.

Key Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Hims & Hers launched generic semaglutide in Canada, giving it first-time international access to the fast-growing GLP-1 market and potentially boosting future sales. Hims & Hers Brings First-Time Access to Generic Semaglutide to Canada
• Positive Sentiment: The company is expanding its personalized care platform with labs, hormone programs, and broader global ambitions, which suggests a larger long-term addressable market. Hims & Hers Deepens Personalized Care Through Platform Expansion
• Positive Sentiment: Analyst coverage turned slightly more constructive after Truist raised its price target to $23 from $18, even though the rating remained Hold. Truist Raises Hims & Hers Price Target
• Neutral Sentiment: Additional coverage noted the Canada GLP-1 launch and broader platform expansion, reinforcing investor attention on growth initiatives rather than new financial results. Reuters Canada semaglutide article
• Negative Sentiment: Some commentary remains cautious after the recent earnings miss and sharp prior pullback, reminding investors that execution risk and valuation concerns are still in focus. MarketBeat earnings miss analysis

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.